WO2024007013A3 - Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof - Google Patents

Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof Download PDF

Info

Publication number
WO2024007013A3
WO2024007013A3 PCT/US2023/069541 US2023069541W WO2024007013A3 WO 2024007013 A3 WO2024007013 A3 WO 2024007013A3 US 2023069541 W US2023069541 W US 2023069541W WO 2024007013 A3 WO2024007013 A3 WO 2024007013A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
polypeptide complexes
methods
cov
sars
Prior art date
Application number
PCT/US2023/069541
Other languages
French (fr)
Other versions
WO2024007013A2 (en
Inventor
Ronnie R. WEI
Chi-Jen Wei
Zhi-Yong Yang
John R. Mascola
Gary J. Nabel
John Misasi
Amarendra PEGU
Lingshu WANG
Tongqing Zhou
Misook CHOE
Olamide K. OLONINIYI
Bingchun ZHAO
Yi Zhang
Eun Sung Yang
Man Chen
Kwanyee LEUNG
Wei Shi
Nancy J. Sullivan
Peter D. Kwong
Richard A. Koup
Barney S. Graham
Original Assignee
Modex Therapeutics, Inc.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutics, Inc., The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical Modex Therapeutics, Inc.
Publication of WO2024007013A2 publication Critical patent/WO2024007013A2/en
Publication of WO2024007013A3 publication Critical patent/WO2024007013A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.
PCT/US2023/069541 2022-06-30 2023-06-30 Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof WO2024007013A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263357336P 2022-06-30 2022-06-30
US63/357,336 2022-06-30
US202263357873P 2022-07-01 2022-07-01
US63/357,873 2022-07-01
US202263404473P 2022-09-07 2022-09-07
US63/404,473 2022-09-07
US202263381850P 2022-11-01 2022-11-01
US63/381,850 2022-11-01
US202263433719P 2022-12-19 2022-12-19
US63/433,719 2022-12-19

Publications (2)

Publication Number Publication Date
WO2024007013A2 WO2024007013A2 (en) 2024-01-04
WO2024007013A3 true WO2024007013A3 (en) 2024-04-18

Family

ID=89381611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069541 WO2024007013A2 (en) 2022-06-30 2023-06-30 Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2024007013A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200262926A1 (en) * 2018-12-24 2020-08-20 Sanofi Multispecific binding proteins with mutant fab domains
US20220017606A1 (en) * 2020-03-12 2022-01-20 Harbour Antibodies Bv Sars-cov-2(sars2, covid-19) antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200262926A1 (en) * 2018-12-24 2020-08-20 Sanofi Multispecific binding proteins with mutant fab domains
US20220017606A1 (en) * 2020-03-12 2022-01-20 Harbour Antibodies Bv Sars-cov-2(sars2, covid-19) antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG LINGSHU, ZHOU TONGQING, ZHANG YI, YANG EUN SUNG, SCHRAMM CHAIM A., SHI WEI, PEGU AMARENDRA, OLONINYI OLAMIDE K., RANSIER AMY,: "Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants", BIORXIV, 1 March 2021 (2021-03-01), XP055955076, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.02.25.432969v2.full.pdf> [retrieved on 20220825], DOI: 10.1101/2021.02.25.432969 *

Also Published As

Publication number Publication date
WO2024007013A2 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
WO2003047506A3 (en) Peptide agonists of prostate-specific antigen, and uses therefor
HK1092481A1 (en) Polypeptides having binding affinity for her2
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
WO2003004622A3 (en) Human secreted proteins
WO2002044215A3 (en) Hybrid antibodies
WO2004024750A3 (en) Cd44-binding ligands
WO2003000865A3 (en) Human secreted proteins
WO2021195598A3 (en) Degrader-antibody conjugates and methods of using same
WO2002083876A3 (en) Secretory molecules
WO2024007012A3 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
WO2024007013A3 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
WO2004052932A3 (en) Antibody (“11c7”) anti nogo a and its pharmaceutical use
CN110066343B (en) Recombinant antigen for detecting new HIV infection and application thereof
WO2023129995A3 (en) Chimeric antigen receptors comprising a pdz binding motif
WO2023122659A3 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
AU6134596A (en) Enamel matrix related polypeptide
MX2023011266A (en) Proteins comprising cd3 antigen binding domains and uses thereof.
WO2023114965A3 (en) Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
MX2022014938A (en) Proteins comprising cd3 antigen binding domains and uses thereof.
WO2005000883A8 (en) Polypeptides having binding affinity for insulin
CA2326407A1 (en) Retroviral vectors including modified envelope escort proteins
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2003042370A3 (en) New gene expressed in prostate cancer and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23832656

Country of ref document: EP

Kind code of ref document: A2